Innovent stock gets USD 1.2 billion Takeda oncology deal
Published on 10/08/2026 at 03:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Innovent stock (ISIN KYG4818G1010) was trading at HKD 98.30 on October 8, 2026, while a new Takeda agreement puts USD 1.2 billion of upfront funding at the center of the company story. The partnership covers two late-stage oncology medicines and gives Innovent a wider route into global development and commercialization.
Takeda brings USD 1.2 billion
According to ET Net on October 5, 2026, Takeda agreed to develop, manufacture and commercialize Innovent's IBI363 and IBI343 outside Greater China. The agreement also gives Takeda an exclusive option covering global rights outside Greater China for the earlier-stage IBI3001 program.
The upfront payment includes a USD 100 million equity investment in Innovent, with additional milestone and royalty payments possible. For IBI363, Takeda and Innovent will share global development costs 60/40, while the same 60/40 split applies to profit or loss in the United States.
Revenue rises 44.8 percent
Innovent's first-half 2026 revenue reached CNY 8.62 billion versus CNY 5.95 billion a year earlier, a 44.8 percent increase. The Wall Street Journal also reported that first-half product revenue grew 55.0 percent year over year to CNY 8.2 billion.
The comparison matters because the Takeda deal adds international development capacity to a business already expanding its commercial base. The main execution risk remains clinical and regulatory: both IBI363 and IBI343 are investigational medicines, so the upfront payment does not remove development uncertainty.
ESMO is the next checkpoint
Innovent is scheduled to present clinical data at the European Society for Medical Oncology meeting from October 23 through October 27, 2026, in Madrid. Yahoo Finance identified IBI363, IBI343, IBI3001 and other pipeline programs among the planned presentations.
Innovent stock trades at HKD 98.30
On the Hong Kong Stock Exchange, Innovent stock was last at HKD 98.30 on October 8, 2026, at 9:29 a.m. HKT, up 0.82 percent from the prior close. Its 52-week range was HKD 69.55 to HKD 112.70, leaving the stock 12.79 percent below the yearly high.
Innovent stock facts
- Company: Innovent Biologics, Inc.
- ISIN: KYG4818G1010
- Ticker: 1801
- Trading venue: HKEX
- Price (as of October 8, 2026, 9:29 a.m. HKT): HKD 98.30
- Market capitalization: HKD 171.1 billion (as of October 8, 2026)
- 52-week range: HKD 69.55-112.70 (as of October 8, 2026)
- Sector / Industry: Health Technology
More news and analysis on Innovent stock
